NYSEAMERICAN:ISR

Isoray - ISR Stock Forecast, Price & News

$0.37

-0.01 (-3.09%)

(As of 11/30/2022 11:19 AM ET)

Add

Compare

Today's Range: $0.37
▼
$0.37
50-Day Range: N/A
52-Week Range: $0.19
▼
$0.51

Volume: 15,200 shs
Average Volume: 337,304 shs
Market Capitalization: $53.01 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Isoray MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$34,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.04) to ($0.02) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Isoray.

5.0

Short Interest

Percentage of Shares Shorted
0.35% of the float of Isoray has been sold short.
Short Interest Ratio / Days to Cover
Isoray has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Isoray has recently decreased by 28.82%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Isoray does not currently pay a dividend.
Dividend Growth
Isoray does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ISR.

2.0

News and Social Media Coverage

News Sentiment
Isoray has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Isoray this week, compared to 1 article on an average week.
Search Interest
6 people have searched for ISR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Isoray to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Isoray insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 2.42% of the stock of Isoray is held by insiders.
Percentage Held by Institutions
Only 11.16% of the stock of Isoray is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Isoray are expected to grow in the coming year, from ($0.04) to ($0.02) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Isoray is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Isoray is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Isoray has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Isoray (NYSEAMERICAN:ISR) Stock

Isoray, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. Isoray, Inc. was founded in 1998 and is based in Richland, Washington.

Receive ISR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.

ISR Stock News Headlines

October 20, 2022 | seekingalpha.com

Isoray Stock: Not Going Anywhere Anytime Soon (NYSE:ISR) - Seeking Alpha

October 18, 2022 | businesswire.com

Isoray Medical, Inc. and Viewpoint Molecular Targeting, Inc. Announce Investor Webcast on October 19, 2022 at 4:15 p.m. EDT - Business Wire

October 16, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, ISR, JVA - Isoray (AMEX:ISR), BTRS H - Benzinga

October 16, 2022 | globenewswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, ISR, JVA - GlobeNewswire

October 15, 2022 | benzinga.com

Lifshitz Law PLLC Announces Investigations of SMBC, ISR, PZN, and BTRS - Isoray (AMEX:ISR), BTRS Holdings (NASDAQ:BTRS) - Benzinga

October 4, 2022 | uk.investing.com

October 4, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTRS, ISR, TALO, RMED - Isoray (AMEX:ISR), BTRS - Benzinga

October 4, 2022 | benzinga.com

October 3, 2022 | benzinga.com

Viewpoint Molecular Targeting Announces VMT- - Isoray (AMEX:ISR) - Benzinga

September 30, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OCSL, SESN, ISR - Isoray (AMEX:ISR), Oaktree Spe - Benzinga

September 29, 2022 | benzinga.com

Lifshitz Law PLLC Announces Investigations of SSNT, ISR, PZN, and BTRS - BTRS Holdings (NASDAQ:BTRS), Isoray (AMEX:ISR) - Benzinga

September 29, 2022 | benzinga.com

Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday’s Mid-Day S - Benzinga

September 29, 2022 | seekingalpha.com

Radiopharmaceutical company Viewpoint to merge with Isoray - Seeking Alpha

September 29, 2022 | benzinga.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCKT, RCOR, TALO, ISR - Isoray (AMEX:ISR), Rocke - Benzinga

September 29, 2022 | finance.yahoo.com

Viewpoint Molecular Targeting Announces Transformational Merger

September 29, 2022 | in.investing.com

After-Hours Movers: Vail Resorts Gains Post EPS, Altus Power Falls on Offering By Investing.com - Investing.com India

September 29, 2022 | investing.com

IsoRay Reports In-Line Q2 EPS By Investing.com - Investing.com

September 29, 2022 | investing.com

IsoRay Earnings, Revenue Miss in Q1 By Investing.com - Investing.com

September 29, 2022 | uk.investing.com

Dow Futures Tick Lower After Indices Recover From Yearly Lows By Investing.com - Investing.com UK

September 29, 2022 | in.investing.com

IsoRay Reports In-Line Q2 EPS By Investing.com - Investing.com India

September 29, 2022 | seekingalpha.com

IsoRay GAAP EPS of -$0.01 in-line, revenue of $2.51M misses by $0.33M (NYSE:ISR) - Seeking Alpha

September 28, 2022 | in.investing.com

IsoRay earnings, Revenue miss in Q1 - Investing.com India

September 28, 2022 | investing.com

Dow Futures Tick Lower After Indices Lift From Yearly Lows By Investing.com - Investing.com

September 28, 2022 | ca.investing.com

IsoRay Reports In-Line Q2 EPS By Investing.com - Investing.com Canada

September 28, 2022 | finance.yahoo.com

IsoRay (ISR) Reports Q4 Loss, Misses Revenue Estimates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ISR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Isoray and its competitors with MarketBeat's FREE daily newsletter.

ISR Company Calendar

Last Earnings: 9/28/2022
Today: 11/30/2022
Fiscal Year End: 6/30/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Surgical & Medical Instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSEAMERICAN:ISR
Previous Symbol: NYSEMKT:ISR
CUSIP: N/A
CIK: 728387
Web: isoray.com
Phone: (509) 375-1202
Fax: 509-267-3670
Employees: 61
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.05)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-3,390,000.00
Net Margins: -48.05%
Pretax Margin: -48.05%
Return on Equity: -9.19%
Return on Assets: -8.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 36.11
Quick Ratio: 35.52

Sales & Book Value

Annual Sales: $10.05 million
Price / Sales: 5.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 0.78

Miscellaneous

Outstanding Shares: 142,113,000
Free Float: 138,481,000
Market Cap: $53.01 million
Optionable: Not Optionable
Beta: 0.92

Key Executives

Ms. Lori A. Holmes-Woods (Age 60)
CEO & Director
Comp: $486k

Ms. Jennifer Streeter (Age 52)
COO & VP of HR
Comp: $366.21k

Mr. William A. Cavanagh III (Age 56)
Chief R&D Officer
Comp: $325.2k

Mr. Jonathan R. Hunt (Age 55)
CFO & Co-Principal Financial Officer

Mr. Mark J. Austin CPA (Age 35)
VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.

Ms. Krista Cline (Age 40)
Sr. Director of Operations & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ISR Stock - Frequently Asked Questions

How have ISR shares performed in 2022?: Isoray's stock was trading at $0.38 on January 1st, 2022. Since then, ISR shares have increased by 1.3% and is now trading at $0.3849.
View the best growth stocks for 2022 here.
Are investors shorting Isoray?: Isoray saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 496,900 shares, a decline of 28.8% from the October 31st total of 698,100 shares. Based on an average daily volume of 309,700 shares, the short-interest ratio is presently 1.6 days. Approximately 0.4% of the shares of the company are short sold.
View Isoray's Short Interest.
How were Isoray's earnings last quarter?: Isoray, Inc. (NYSEAMERICAN:ISR) announced its quarterly earnings results on Wednesday, September, 28th. The healthcare company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The healthcare company earned $2.51 million during the quarter, compared to analyst estimates of $2.89 million. Isoray had a negative net margin of 48.05% and a negative trailing twelve-month return on equity of 9.19%.
What other stocks do shareholders of Isoray own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Isoray investors own include Brainstorm Cell Therapeutics (BCLI), OPKO Health (OPK), Bausch Health Companies (BHC), Anavex Life Sciences (AVXL), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MannKind (MNKD), CTI BioPharma (CTIC), Idera Pharmaceuticals (IDRA) and Palatin Technologies (PTN).

What is Isoray's stock symbol?: Isoray trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ISR."
Who are Isoray's major shareholders?: Isoray's stock is owned by many different retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (2.01%). Insiders that own company stock include Jonathan Robert Hunt, Lori A Woods, Mark John Austin, Michael Krachon and Philip J Vitale.
View institutional ownership trends.
How do I buy shares of Isoray?: Shares of ISR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Isoray's stock price today?: One share of ISR stock can currently be purchased for approximately $0.38.
How much money does Isoray make?: Isoray (NYSEAMERICAN:ISR) has a market capitalization of $54.70 million and generates $10.05 million in revenue each year. The healthcare company earns $-3,390,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis.
How can I contact Isoray?: Isoray's mailing address is 350 Hills St Ste 106, RICHLAND, WA 99354-5511, United States. The official website for the company is isoray.com. The healthcare company can be reached via phone at (509) 375-1202, via email at dbabcock@isoray.com, or via fax at 509-267-3670.

This page (NYSEAMERICAN:ISR) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Isoray - ISR Stock Forecast, Price & News

Isoray MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Isoray (NYSEAMERICAN:ISR) Stock

ISR Stock News Headlines

ISR Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ISR Stock - Frequently Asked Questions

Overall MarketRank^™